Autocrine prolactin promotes prostate cancer cell growth via Janus kinase-2-signal transducer and activator of transcription-5a/b signaling pathway

Endocrinology

Volumn 148, Issue 7, 2007, Pages 3089-3101

  Dagvadorj, Ayush ^a   Collins, Sean ^b   Jomain, Jean Baptiste ^c   Abdulghani, Junaid ^a   Karras, James ^d   Zellweger, Tobias ^e   Li, Hongzhen ^b   Nurmi, Martti ^f   Alanen, Kalle ^g   Mirtti, Tuomas ^g   Visakorpi, Tapio ^h   Bubendorf, Lukas ⁱ   Goffin, Vincent ^c   Nevalainen, Marja T ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

^c INSERM   (France)

^d ISIS PHARMACEUTICALS   (United States)

^e UNIVERSITY OF BASEL   (Switzerland)

^f TURKU UNIVERSITY HOSPITAL   (Finland)

^g UNIVERSITY OF TURKU   (Finland)

^h UNIVERSITY OF TAMPERE   (Finland)

ⁱ UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2; PROLACTIN; PROLACTIN RECEPTOR ANTAGONIST; RECEPTOR BLOCKING AGENT; STAT5 PROTEIN; TRANSCRIPTION FACTOR PIT 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CELL VIABILITY; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; METASTASIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANIMALS; CELL LINE, TUMOR; CELL SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOBLOTTING; JANUS KINASE 2; MALE; MICE; MICE, NUDE; NEOPLASM METASTASIS; NEOPLASMS, EXPERIMENTAL; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; PHOSPHORYLATION; PROLACTIN; PROMOTER REGIONS (GENETICS); PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STAT5 TRANSCRIPTION FACTOR; TRANSCRIPTION, GENETIC; TRANSPLANTATION, HETEROLOGOUS; TYRPHOSTINS;

EID: 34347271908     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2006-1761     Document Type: Article

References (42)

1. Linja MJ, Visakorpi T 2004 Alterations of androgen receptor in prostate cancer. J Steroid Biochem Mol Biol 92:255-264
2. Feldman BJ, Feldman D 2001 The development of androgen-independent prostate cancer. Nat Rev Cancer 1:34-45
3. Nevalainen MT, Valve EM, Ingleton PM, Harkonen PL 1996 Expression and hormone regulation of prolactin receptors in rat dorsal and lateral prostate. Endocrinology 137:3078-3088
4. Nevalainen MT, Valve EM, Ingleton PM, Nurmi M, Martikainen PM, Harkonen PL 1997 Prolactin and prolactin receptors are expressed and functioning in human prostate. J Clin Invest 99:618-627
5. Li H, Ahonen TJ, Alanen K, Xie J, LeBaron MJ, Pretlow TG, Ealley EL, Zhang Y, Nurmi M, Singh B, Martikainen PM, Nevalainen MT 2004 Activation of signal transducer and activator of transcription 5 in human prostate cancer is associated with high histological grade. Cancer Res 64:4774-4782
6. DiMattia G, Gellersen B, Duckworth ML, Friesen HG 1990 Human prolactin gene expression. J Biol Chem 265:16412-16421
7. Ben-Jonathan N, Mershon J, Allen DL, Steinmetz RW 1996 Extrapituitary prolactin: distribution, regulation, functions, and clinical aspects. Endocr Rev 17:639-669
8. Baudhuin A, Manfroid I, Van De Weerdt C, Martial JA, Muller M 2002 Transcription of the human prolactin gene in mammary cells. Ann NY Acad Sci 973:454-458
9. Ben-Jonathan N, Liby K, McFarland M, Zinger M 2002 Prolactin as an autocrine/paracrine growth factor in human cancer. Trends Endocrinol Metab 13:245-263
10. Gerlo S, Davis JR, Mager DL, Kooijman R 2006 Prolactin in man: a tale of two promoters. Bioessays 28:1051-1055
11. Nevalainen MT, Valve EM, Ingleton PM, Nurmi M, Martikainen PM, Harkonen PL 1997 Androgen-dependent expression of prolactin in rat prostate epithelium in vivo and in organ culture. FASEB J 11:1297-1308
12. Nevalainen MT, Valve EM, Makela SI, Blauer M, Tuohimaa PJ, Harkonen PL 1991 Estrogen and prolactin regulation of rat dorsal and lateral prostate in organ culture. Endocrinology 129:612-622
13. Ahonen TJ, Harkonen PL, Laine J, Rui H, Martikainen PM, Nevalainen MT 1999 Prolactin is a survival factor for androgen-deprived rat dorsal and lateral prostate epithelium in organ culture. Endocrinology 140:5412-5421
14. Wennbo H, Kindblom J, Isaksson OG, Tornell J 1997 Transgenic mice overexpressing the prolactin gene develop dramatic enlargement of the prostate gland. Endocrinology 138:4410-4415
15. Kindblom J, Dillner K, Ling C, Tornell J, Wennbo H 2002 Progressive prostate hyperplasia in adult prolactin transgenic mice is not dependent on elevated serum androgen levels. Prostate 53:24-33
16. Kindblom J, Dillner K, Sahlin L, Robertson F, Ormandy C, Tornell J, Wennbo H 2003 Prostate hyperplasia in a transgenic mouse with prostate-specific expression of prolactin. Endocrinology 144:2269-2278
17. Janssen T, Darro F, Petein M, Raviv G, Pasteels JL, Kiss R, Schulman CC 1996 In vitro characterization of prolactin-induced effects on proliferation in the neoplastic LNCaP, DU145, and PC3 models of the human prostate. Cancer 77:144-149
18. Steger RW, Chandrashekar V, Zhao W, Bartke A, Horseman ND 1998 Neuroendocrine and reproductive functions in male mice with targeted disruption of the prolactin gene. Endocrinology 139:3691-3695
19. Ahonen TJ, Harkonen PL, Rui H, Nevalainen MT 2002 PRL signal transduction in the epithelial compartment of rat prostate maintained as long-term organ cultures in vitro. Endocrinology 143:228-238
20. Ahonen TJ, Xie J, LeBaron MJ, Zhu J, Nurmi M, Alanen K, Rui H, Nevalainen MT 2003 Inhibition of transcription factor Stat5 induces cell death of human prostate cancer cells. J Biol Chem 278:27287-27292
21. Kazansky AV, Spencer DM, Greenberg NM 2003 Activation of signal transducer and activator of transcription 5 is required for progression of autochthonous prostate cancer: evidence from the transgenic adenocarcinoma of the mouse prostate system. Cancer Res 63:8757-8762
22. Xu X, Kreye E, Kuo CB, Walker AM 2001 A molecular mimic of phosphorylated prolactin markedly reduced tumor incidence and size when du145 human prostate cancer cells were grown in nude mice. Cancer Res 61:6098-6104
23. Goffin V, Bernichtein S, Touraine P, Kelly PA 2005 Development and potential clinical uses of human prolactin receptor antagonists. Endocr Rev 26:400-422
24. Wu W, Ginsburg E, Vonderhaar BK, Walker AM 2005 S179D prolactin increases vitamin D receptor and p21 through up-regulation of short 1b prolactin receptor in human prostate cancer cells. Cancer Res 65:7509-7515
25. Goffin V, Touraine P, Culler MD, Kelly PA 2006 Drug insight: prolactin-receptor antagonists, a novel approach to treatment of unresolved systemic and local hyperprolactinemia? Nat Clin Pract Endocrinol Metab 2:571-581
26. Bernichtein S, Kayser C, Dillner K, Moulin S, Kopchick JJ, Martial JA, Norstedt G, Isaksson O, Kelly PA, Goffin V 2003 Development of pure prolactin receptor antagonists. J Biol Chem 278:35988-35999
27. Saramaki O, Willi N, Bratt O, Gasser TC, Koivisto P, Nupponen NN, Bubendorf L, Visakorpi T 2001 Amplification of EIF3S3 gene is associated with advanced stage in prostate cancer. Am J Pathol 159:2089-2094
28. Zellweger T, Ninck C, Bloch M, Mirlacher M, Koivisto PA, Helin HJ, Mihatsch MJ, Gasser TC, Bubendorf L 2005 Expression patterns of potential therapeutic targets in prostate cancer. Int J Cancer 113:619-628
29. Behbod F, Nagy ZS, Stepkowski SM, Karras J, Johnson CR, Jarvis WD, Kirken RA 2003 Specific inhibition of Stat5a/b promotes apoptosis of IL-2-responsive primary and tumor-derived lymphoid cells. J Immunol 171:3919-3927
30. Stevens A, Ray D, Alansari A, Hajeer A, Thomson W, Donn R, Ollier WE, Worthington J, Davis JR 2001 Characterization of a prolactin gene polymorphism and its associations with systemic lupus erythematosus. Arthritis Rheum 44:2358-2366
31. Li H, Zhang Y, Glass A, Zellweger T, Gehan E, Bubendorf L, Gelmann EP, Nevalainen MT 2005 Activation of signal transducer and activator of transcription-5 in prostate cancer predicts early recurrence. Clin Cancer Res 11:5863-5868
32. Truong AT, Duez C, Belayew A, Renard A, Pictet R, Bell GI, Martial JA 1984 Isolation and characterization of the human prolactin gene. EMBO J 3:429-437
33. Van De Weerdt C, Peers B, Belayew A, Martial JA, Muller M 2000 Far upstream sequences regulate the human prolactin promoter transcription. Neuroendocrinology 71:124-137
34. Pretlow TG, Wolman SR, Micale MA, Pelley RJ, Kursh ED, Resnick MI, Bodner DR, Jacobberger JW, Delmoro CM, Giaconia JM, et al 1993 Xenografts of primary human prostatic carcinoma. J Natl Cancer Inst 85:394-398
35. Wainstein MA, He F, Robinson D, Kung HJ, Schwartz S, Giaconia JM, Edgehouse NL, Pretlow TP, Bodner DR, Kursh ED, et al 1994 CWR22: androgen-dependent xenograft model derived from a primary human prostatic carcinoma. Cancer Res 54:6049-6052
36. Nagabhushan M, Miller CM, Pretlow TP, Giaconia JM, Edgehouse NL, Schwartz S, Kung HJ, de Vere White RW, Gumerlock PH, Resnick MI, Amini SB, Pretlow TG 1996 CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar. Cancer Res 56:3042-3046
37. Ryan AK, Rosenfeld MG 1997 POU domain family values: flexibility, partnerships, and developmental codes. Genes Dev 11:1207-1225
38. Kaulsay KK, Zhu T, Bennett W, Lee KO, Lobie PE 2001 The effects of autocrine human growth hormone (hGH) on human mammary carcinoma cell behavior are mediated via the hGH receptor. Endocrinology 142:767-777
39. Xie J, LeBaron MJ, Nevalainen MT, Rui H 2002 Role of tyrosine kinase Jak2 in prolactin-induced differentiation and growth of mammary epithelial cells. J Biol Chem 277:14020-14030
40. Gouilleux F, Wakao H, Mundt M, Groner B 1994 Prolactin induces phosphorylation of Tyr694 of Stat5 (MGF), a prerequisite for DNA binding and induction of transcription. EMBO J 13:4361-4369
41. Craft N, Chhor C, Tran C, Belldegrun A, DeKernion J, Witte ON, Said J, Reiter RE, Sawyers CL 1999 Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. Cancer Res 59:5030-5036
42. Nickerson T, Chang F, Lorimer D, Smeekens SP, Sawyers CL, Pollak M 2001 In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor-I (IGF-I) and IGF-I receptor (IGF-IR). Cancer Res 61:6276-6280